AFP and hepatocellular carcinoma: For example, in hepatocellular carcinoma (HCC) models, the combination of an alpha-fetoprotein (AFP) vaccine and anti-PD-L1 therapy led to significant inhibition of tumor progression in the majority of liver lesions, indicating that vaccine-primed T-cell responses can be effectively activated by checkpoint blockade 84.